AstraZeneca Expands Texas Manufacturing Facility
AstraZeneca has expanded its Coppell site with a $445 million investment to double production of Lokelma, a drug used to treat hyperkalemia.
The expansion will boost global production capacity, enhance local job growth, and strengthen the company's US manufacturing footprint.
- The Coppell plant is the only manufacturing facility producing Lokelma worldwide, shipping to over 50 countries.
- The facility currently houses 250 employees and will increase by 9,000 square feet.
- The expansion includes two new manufacturing lines, laboratory testing, warehousing, and administrative space.
Lokelma—sodium zirconium cyclosilicate—is used to treat hyperkalemia, high potassium levels in the blood.
AstraZeneca's investment is part of industry-wide onshoring trends, enhancing the company's US manufacturing presence.
Author's summary: AstraZeneca invests $445 million to expand Texas facility.
More News
- Leylah Fernandez lifts fifth career title with Japan Open win
- How to teach Dragon Ascent to Rayquaza - Pokémon Go? - TechStory
- YOUR SUNDAY READING LIST: Emergency Nudity, ICE on Parade, and Portland's Hero Frogs
- Keanu Reeves Just Responded to Those Alexandra Grant Marriage Rumors
- Como 2-0 Juventus: Nico Paz puts toothless Old Lady to the torch
- Nico Paz decisive: Juve loses in Como before Bernabéu visit